MABLINK BIOSCIENCE

One line pitch:
Next Generation ADC Expert. Mablink’s approach to build next generation Antibody-Drug Conjugates (ADCs) relies on a proprietary hydrophilic chemical linker platform which confers hydrophobicity masking properties to the drug linker couple.

Addressed market and international ambitions:
The ADC clinical market will be of $22 billion in 2022. The ADC R&D market represent more than $2.5 billion every year. It is in this market that Mablink wishes to become a major player. Today, Mablink works mostly with USA, UK and France. It is not currently planned to have subsidiaries in other countries. The most important for us today is to continue to communicate on our technology and to build many partnerships around the world.

Your team:
- Our innovation derives from the invention of Dr W. Viricel who had the idea to use a new material in a pharmacological context. His meeting with Pr B. Joseph and Pr C. Dumontet allows him to achieve his idea and to realize the POC.

Value proposition:
we can overcome no less than 7 pharmacological limitations in the field: exceeding current limits in term of number of coupled toxins, homogeneity of the final compound, plasma stability, better therapeutic index, technology directly applicable to any native antibody, compatible with every toxins. Finally, another very important parameter, is the reduction of cost and of manufacturing time from 10 months to 2 weeks with our technology.

Business model:
Mablink business model is double: We have our own R&D program to develop new drug-candidates. Two important programs are in progress (MBK-101 & MBK-102). In addition, Mablink propose to licence its technology to actors of the field that wants to overcome the current technological barriers they have to face.

IP and regulatory situation:
Mablink technology is protected under the patent and the PCT deposit has already been completed and published. The geographical area covered are very wide.

COMPANY PROFILE
Website:
https://www.mablink.com

Category:
Bio & Health

Contact:
Jean-Guillaume Lafay
jg.lafay@mablink.com

Location:
France

Founded in:
2018-12-04

Employees:
4

Financial information (€):
- Stage: go-to-market
- Capital raised to date: 125k€ + 1 100k€ (R&D programs, i-LAB, FTS and others)
- Annual revenue: we do not want to share our income.